Table 3.
Baseline characteristics separated by fracture status including fracture type, biochemistry and medication
| Patient characteristics | |||
|---|---|---|---|
| Patients with history of fracture (n = 32) |
Patients without history of fracture (n = 50) |
p-value | |
| Women | 13 | 17 | 0.54 |
| Men | 19 | 33 | 0.54 |
| Age, years | 58.6 ± 15.3 | 55.4 ± 14.2 | 0.34 |
| BMI, kg/m2 | 26.1 ± 5.4 | 27.1 ± 6.1 | 0.42 |
| Dialysis duration, months | 84.8 ± 51.7 | 66.6 ± 55.2 | 0.14 |
| Hemodialysis | 20 (62.5%) | 21 (42%) | 0.07 |
| Peritoneal dialysis | 12 (37.5%) | 29 (58%) | 0.07 |
| History of kidney transplantation | 12 (37.5%) | 15 (30%) | 0.48 |
| Musculoskeletal pain | 21 (65.6%) | 15 (30%) | 0.002 |
| Previous fracture | 32 (100%) | 0 (0%) | – |
| Proximal femur fracture | 5 (15.6%) | 0 (0%) | – |
| Vertebral fracture | 14 (43.8%) | 0 (0%) | – |
| Peripheral fracture | 19 (59.4%) | 0 (0%) | – |
| Biochemistry | |||
| Parathyroid hormone, pg/ml | 408.3 ± 208.8 | 407.9 ± 189.2 | 0.99 |
| Alkaline phosphatase, U/L | 89.4 ± 33.8 | 95.3 ± 41.2 | 0.48 |
| Calcium, mmol/l | 2.24 ± 0.20 | 2.25 ± 0.18 | 0.86 |
| Ionized calcium, mmol/l | 1.15 ± 0.11 | 1.15 ± 0.10 | 0.88 |
| Phosphate, mg/dl | 5.16 ± 0.90 | 5.13 ± 1.22 | 0.92 |
| 25-OH-vitamin D, ng/ml | 25.4 ± 12.3 | 27.3 ± 11.3 | 0.49 |
| Medication | |||
| Cinacalcet | 7 (21.9%) | 17 (34.0%) | 0.24 |
|
Phosphate binder: Aluminum salts |
2 (6.3%) | 2 (4.0%) | 0.65 |
|
Phosphate binder: Calcium carbonate/acetate |
13 (40.6%) | 19 (38.0%) | 0.81 |
|
Phosphate binder: Lanthanum carbonate |
7 (21.9%) | 9 (18.0%) | 0.67 |
|
Phosphate binder: Sevelamer hydrochloride/carbonate |
8 (25.0%) | 20 (40.0%) | 0.16 |
bold values reached statistical significance